|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.42 USD | +1.79% |
|
+3.04% | +29.62% |
| 12-03 | Pacira Biosciences reports inducement grants under Nasdaq Listing Rule | RE |
| 12-02 | Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain | MT |
| Capitalization | 1.05B 904M 849M 789M 1.45B 94.71B 1.59B 9.89B 3.83B 44.72B 3.94B 3.86B 164B | P/E ratio 2025 * |
41.2x | P/E ratio 2026 * | 14.1x |
|---|---|---|---|---|---|
| Enterprise value | 1.17B 1.01B 947M 880M 1.62B 106B 1.77B 11.03B 4.27B 49.87B 4.4B 4.3B 183B | EV / Sales 2025 * |
1.6x | EV / Sales 2026 * | 1.37x |
| Free-Float |
96.11% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Pacira BioSciences, Inc.
| 1 day | +1.79% | ||
| 1 week | +3.04% | ||
| Current month | +3.61% | ||
| 1 month | +10.75% | ||
| 3 months | -8.68% | ||
| 6 months | -5.97% | ||
| Current year | +29.62% |
| 1 week | 23.63 |  | 24.81 |
| 1 month | 21.68 | | 24.95 |
| Current year | 18.17 | | 27.64 |
| 1 year | 18.17 | | 27.64 |
| 3 years | 11.16 | | 48.6 |
| 5 years | 11.16 | | 82.16 |
| 10 years | 11.16 | | 82.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 57 | 01/01/2024 |
Shawn Cross
DFI | Director of Finance/CFO | 57 | 20/10/2024 |
Anthony Molloy
CMP | Compliance Officer | 51 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Laura Brege
CHM | Chairman | 67 | 27/01/2025 |
Mark Kronenfeld
BRD | Director/Board Member | 70 | 11/06/2013 |
Mark Froimson
BRD | Director/Board Member | 64 | 14/06/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.24% | 22 M€ | +0.95% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.79% | +3.04% | +26.73% | -48.17% | 1.03B | |
| -1.26% | -5.70% | +20.67% | +168.32% | 905B | |
| -0.15% | -1.81% | +35.03% | +13.78% | 487B | |
| -1.31% | -0.88% | +26.64% | +34.42% | 400B | |
| +2.19% | +3.35% | +23.62% | +5.48% | 330B | |
| -0.10% | -2.83% | +27.45% | +20.61% | 281B | |
| -0.41% | +2.07% | +18.74% | +24.32% | 255B | |
| -0.79% | -2.85% | -4.04% | -10.75% | 248B | |
| -3.42% | -5.68% | -61.94% | -32.73% | 214B | |
| -2.63% | -4.82% | +17.85% | +12.49% | 178B | |
| Average | -0.63% | -1.82% | +13.07% | +18.78% | 329.76B | |
| Weighted average by Cap. | -0.80% | -2.79% | +16.86% | +54.29% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 730M 628M 590M 548M 1.01B 65.82B 1.1B 6.88B 2.66B 31.08B 2.74B 2.68B 114B | 797M 686M 644M 598M 1.1B 71.81B 1.2B 7.5B 2.9B 33.91B 2.99B 2.93B 124B |
| Net income | 25.92M 22.31M 20.95M 19.47M 35.89M 2.34B 39.16M 244M 94.52M 1.1B 97.28M 95.2M 4.04B | 78.21M 67.32M 63.2M 58.75M 108M 7.05B 118M 736M 285M 3.33B 294M 287M 12.2B |
| Net Debt | 121M 104M 97.86M 90.97M 168M 10.92B 183M 1.14B 442M 5.15B 455M 445M 18.88B | 39.01M 33.58M 31.52M 29.3M 54.01M 3.52B 58.93M 367M 142M 1.66B 146M 143M 6.08B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/12/25 | 24.42 $ | +1.79% | 727,234 |
| 05/12/25 | 23.99 $ | +0.04% | 424,015 |
| 04/12/25 | 23.98 $ | -0.87% | 573,725 |
| 03/12/25 | 24.19 $ | +0.50% | 552,877 |
| 02/12/25 | 24.07 $ | +1.56% | 1,023,502 |
Delayed Quote Nasdaq, December 08, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PCRX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition